Scholar Rock Holding Corp 正积极与欧洲药品管理局（EMA）展开沟通。该公司旨在将第二处灌装-封装生产设施，纳入其实验性药物Apitegromab的上市许可申请（MAA）中。这一举措，凸显了其对于扩大生产能力的战略布局。通过此举，公司期望能优化供应链韧性，并确保未来药物获批后的稳定供应。此举不仅关乎生产规模，更体现了对监管流程的深度参与与前瞻性规划。
Scholar Rock Holding Corp 正积极与欧洲药品管理局（EMA）展开沟通。该公司旨在将第二处灌装-封装生产设施，纳入其实验性药物Apitegromab的上市许可申请（MAA）中。这一举措，凸显了其对于扩大生产能力的战略布局。通过此举，公司期望能优化供应链韧性，并确保未来药物获批后的稳定供应。此举不仅关乎生产规模，更体现了对监管流程的深度参与与前瞻性规划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.